81 related articles for article (PubMed ID: 21533343)
41. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
Takahashi N; Li WW; Banerjee D; Scotto KW; Bertino JR
Clin Cancer Res; 2001 Oct; 7(10):3251-7. PubMed ID: 11595721
[TBL] [Abstract][Full Text] [Related]
42. Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro.
Ohkawa K; Hatano T; Tsukada Y; Matsuda M
Br J Cancer; 1993 Feb; 67(2):274-8. PubMed ID: 8431358
[TBL] [Abstract][Full Text] [Related]
43. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin.
Kawano H; Komaba S; Yamasaki T; Maeda M; Kimura Y; Maeda A; Kaneda Y
Cancer Chemother Pharmacol; 2008 May; 61(6):973-8. PubMed ID: 17653716
[TBL] [Abstract][Full Text] [Related]
44. Caspase-3 activation during apoptosis caused by glutathione-doxorubicin conjugate.
Asakura T; Sawai T; Hashidume Y; Ohkawa Y; Yokoyama S; Ohkawa K
Br J Cancer; 1999 May; 80(5-6):711-5. PubMed ID: 10360648
[TBL] [Abstract][Full Text] [Related]
45. Effects of liposomal phospholipids and lipid transport-related protein on the intracellular fate of encapsulated doxorubicin.
Un K; Sakai-Kato K; Kawanishi T; Okuda H; Goda Y
Mol Pharm; 2014 Feb; 11(2):560-7. PubMed ID: 24383572
[TBL] [Abstract][Full Text] [Related]
46. Prolongation of murine cardiac allograft survival with vesnarinone.
Hirozane T; Matsumori A; Furukawa Y; Matsui S; Matoba Y; Sasayama S
J Mol Cell Cardiol; 1997 Jan; 29(1):67-76. PubMed ID: 9040022
[TBL] [Abstract][Full Text] [Related]
47. Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice.
Mizuno Y; Naoi T; Nishikawa M; Rattanakiat S; Hamaguchi N; Hashida M; Takakura Y
J Control Release; 2010 Jan; 141(2):252-9. PubMed ID: 19778560
[TBL] [Abstract][Full Text] [Related]
48. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma.
Ohkawa K; Hatano T; Yamada K; Joh K; Takada K; Tsukada Y; Matsuda M
Cancer Res; 1993 Sep; 53(18):4238-42. PubMed ID: 8364920
[TBL] [Abstract][Full Text] [Related]
49. Effects of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212) and its solvent sulfolane on isolated heart preparations of the rat, guinea pig, and dog.
Grupp G; Grupp IL; Newman G; Schwartz A
Arzneimittelforschung; 1984; 34(3A):359-63. PubMed ID: 6540089
[TBL] [Abstract][Full Text] [Related]
50. Doxorubicin increases oxidative metabolism in HL-1 cardiomyocytes as shown by 13C metabolic flux analysis.
Strigun A; Wahrheit J; Niklas J; Heinzle E; Noor F
Toxicol Sci; 2012 Feb; 125(2):595-606. PubMed ID: 22048646
[TBL] [Abstract][Full Text] [Related]
51. Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, on the dog heart.
Taira N; Endoh M; Iijima T; Satoh K; Yanagisawa T; Yamashita S; Maruyama M; Kawada M; Morita T; Wada Y
Arzneimittelforschung; 1984; 34(3A):347-55. PubMed ID: 6331465
[TBL] [Abstract][Full Text] [Related]
52. Protective effects of the exopolysaccharide Lasiodiplodan against DNA damage and inflammation induced by doxorubicin in rats: Cytogenetic and gene expression assays.
Mello MB; Machado CS; Ribeiro DL; Aissa AF; Burim RV; Alves da Cunha MA; Barcelos GR; Antunes LM; Bianchi ML
Toxicology; 2017 Feb; 376():66-74. PubMed ID: 27181935
[TBL] [Abstract][Full Text] [Related]
53. Clinical characteristics of vesnarinone.
Feldman AM
Drug Saf; 2004; 27 Suppl 1():1-9. PubMed ID: 15293848
[TBL] [Abstract][Full Text] [Related]
54. Vesnarinone: a differentiation-inducing anti-cancer drug.
Kawamata H; Omotehara F; Nakashiro K; Uchida D; Hino S; Fujimori T
Anticancer Drugs; 2003 Jul; 14(6):391-5. PubMed ID: 12853878
[TBL] [Abstract][Full Text] [Related]
55. Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicin.
Pinna A; Agen C; Di Paolo A; Innocenti F; Nardini D; Danesi R; Del Tacca M
J Environ Pathol Toxicol Oncol; 1994; 13(1):25-31. PubMed ID: 7823290
[TBL] [Abstract][Full Text] [Related]
56. Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture.
Hattori Y; So S; Hattori S; Kasai K; Shimoda S
Cardiovasc Res; 1995 Aug; 30(2):187-92. PubMed ID: 7585804
[TBL] [Abstract][Full Text] [Related]
57. In vitro enhancement of doxorubicin genotoxic activities and interference with cell cycle delay by Plumbago indica root ethanolic extract in human lymphocytes.
Ratanavalachai T; Thitiorul S; Tanuchit S; Itharat A; Sakpakdeejaroen I
J Med Assoc Thai; 2015 Mar; 98 Suppl 2():S38-44. PubMed ID: 26211102
[TBL] [Abstract][Full Text] [Related]
58. Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres.
Venditti P; Balestrieri M; De Leo T; Di Meo S
Cardiovasc Res; 1998 Jun; 38(3):695-702. PubMed ID: 9747437
[TBL] [Abstract][Full Text] [Related]
59. Involvement of advanced glycation end-products, pentosidine and N(epsilon)-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats.
Moriyama T; Kemi M; Okumura C; Yoshihara K; Horie T
Toxicology; 2010 Jan; 268(1-2):89-97. PubMed ID: 20004697
[TBL] [Abstract][Full Text] [Related]
60. [Effects of vesnarinone on L-type single Ca2+ channel current in cultured ventricular myocytes of embryonic chick].
Zhang Y; Li H; Lan T; Zeng X
Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):403-7. PubMed ID: 8732061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
